Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously ...

The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with ...

Researchers are beginning to wonder whether blockbuster drugs such as Wegovy, Ozempic and Zepbound could play a role in ...

(2016) for its economic base case. The NHS Clinical Lead for the Cancer Drugs Fund reported that 262 people have had dostarlimab with carboplatin and paclitaxel since it has been in the Cancer Drugs ...

The discontinued drug belongs to a class of ... which was being tested in combination with GSK's dostarlimab for treating advanced non-small cell lung cancer (NSCLC), did not demonstrate ...

Researchers at Memorial Sloan Kettering Cancer Center gave the drug dostarlimab to 117 patients who have tumors that carry mismatch repair mutations, a rare condition that accounts for about 2% to 3% ...

in combination with dostarlimab, with or without docetaxel, in advanced non-small cell lung cancer (NSCLC). The first patient has been dosed in the study, which aims to evaluate the safety of the drug ...

A new study found that the immunotherapy treatment worked against some types of cancers, allowing patients to avoid surgery and other types of more invasive treatment to cure their disease.

This phase 2 study builds on previous landmark research, in which colorectal cancer patients receiving the immunotherapy drug dostarlimab experienced complete tumor remission. In recognition of ...